Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study.

Curtis, Jeffrey R; Chakravarty, Soumya D; Black, Shawn; Kafka, Shelly; Xu, Stephen; Langholff, Wayne; Parenti, Dennis; Greenspan, Andrew; Schwartzman, Sergio

Curtis, Jeffrey R; Chakravarty, Soumya D; Black, Shawn; Kafka, Shelly; Xu, Stephen; Langholff, Wayne; Parenti, Dennis; Greenspan, Andrew; Schwartzman, Sergio.

Afiliação

Curtis JR; University of Alabama at Birmingham, Birmingham, AL, USA.
Chakravarty SD; Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA, 19044, USA. schakr66@its.jnj.com.
Black S; Drexel University College of Medicine, Philadelphia, PA, USA. schakr66@its.jnj.com.
Kafka S; Janssen Research & Development, LLC, Spring House, PA, USA.
Xu S; Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA, 19044, USA.
Langholff W; Janssen Research & Development, LLC, Spring House, PA, USA.
Parenti D; Janssen Research & Development, LLC, Spring House, PA, USA.
Greenspan A; Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA, 19044, USA.
Schwartzman S; Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA, 19044, USA.

Rheumatol Ther ; 8(4): 1551-1563, 2021 Dec.

Article em En | MEDLINE | ID: mdl-34417735

Palavras-chave

Clinical disease activity index; Infliximab; Infusion reaction; Intravenous golimumab; Real-world evidence

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Incidence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Rheumatol Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google